Sarah H. O'BRien

Sarah H. O'BRien

Auto-generated profile, based on publicly available information

Sarah H. O'BRien

Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital and The Ohio State University, College of Medicine, Columbus, Ohio; Center for Child Health Equity and Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Blood Advances
Verified
Journal Article
Closed access
NCNathan T. Connell
Nathan T. Connell
VFVeronica H. Flood
Veronica H. Flood
RBRomina Brignardello-Petersen
Romina Brignardello-Petersen
RARezan Abdul-Kadir
Rezan Abdul-Kadir
AAAlice Arapshian
Alice Arapshian
RMReem A. Mustafa
Reem A. Mustafa
Background: von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients.Objective: These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD.Methods: ASH, ISTH, NHF, and WFH formed a multidisciplinary guideline panel. Three patient representatives were included. The panel was balanced to minimize potential bias from conflicts of interest. The University of Kansas Outcomes and Implementation Research Unit and the McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing and updating systematic evidence reviews (through November 2019). The panel prioritized clinical questions and outcomes according to their importance to clinicians and patients. The panel used the GRADE approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.Results: The panel agreed on 12 recommendations and outlined future research priorities.Conclusions: These guidelines make key recommendations regarding prophylaxis for frequent recurrent bleeding, desmopressin trials to determine therapy, use of antiplatelet agents and anticoagulant therapy, target VWF and factor VIII activity levels for major surgery, strategies to reduce bleeding during minor surgery or invasive procedures, management options for heavy menstrual bleeding, management of VWD in the context of neuraxial anesthesia during labor and delivery, and management in the postpartum setting.

1 November 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
NGNeil A. Goldenberg
Neil A. Goldenberg
ASAnthony Sochet
Anthony Sochet
MAManuela Albisetti
Manuela Albisetti
TBTina Biss
Tina Biss
MBMariana Bonduel
Mariana Bonduel
CMChristoph Male
Christoph Male

22 December 2010 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
SCSean D. Candrilli
Sean D. Candrilli
SOSarah H. O'BRien
Sarah H. O'BRien
RWRussell E. Ware
Russell E. Ware
MNMilap C. Nahata
Milap C. Nahata
ESEric E. Seiber
Eric E. Seiber
RBRajesh Balkrishnan
Rajesh Balkrishnan
While laboratory and clinical benefits of hydroxyurea for patients with sickle cell disease (SCD) are well‐established, few data describe the extent and implications of non‐adherence. We sought to assess adherence to hydroxyurea among patients with SCD and investigate associations between adherence and clinical and economic outcomes. Insurance claims of North Carolina Medicaid enrollees (6/2000‐8/2008) with SCD were analyzed. Inclusion criteria included age <65 years, continuous Medicaid enrollment ≥12 months before and following hydroxyurea initiation, and ≥2 hydroxyurea prescriptions. Three hundred twelve patients, mean age 21 (±12.2) years, met inclusion criteria and 35% were adherent, defined as a medication possession ration (MPR) ≥ 0.80; mean MPR was 0.60. In the 12 months following hydroxyurea initiation, adherence was associated with reduced risk of SCD‐related hospitalization (hazard ratio [HR] = 0.65, p = .0351), all‐cause and SCD‐related emergency department visit (HR = 0.72, p = .0388; HR = 0.58, p =.0079, respectively), and vaso‐occlusive event (HR = 0.66, p = .0130). Adherence was associated with reductions in health care costs such as all‐cause and SCD‐related inpatient (−$5,286, p < .0001; −$4,403, p < .0001, respectively), ancillary care (−$1,336, p < .0001; −$836, p < .0001, respectively), vaso‐occlusive event‐related (−$5,793, p < .0001), and total costs (−$6,529, p < .0001; −$5,329, p <.0001, respectively). Adherence to hydroxyurea among SCD patients appears suboptimal and better adherence is associated with improved clinical and economic outcomes. Am. J. Hematol. 2011.

14 February 2022 in Pediatrics
Verified
Journal Article
Closed access
PDF file
SOSarah H O’bRien
Sarah H O’bRien
JSJoseph R Stanek
Joseph R Stanek
CWChar M Witmer
Char M Witmer
LRLeslie Raffini
Leslie Raffini
In 2009, a large multicenter study demonstrated that the rate of pediatric venous thromboembolism (VTE) across US children’s hospitals had significantly increased from 2001 to 2007. The objective of this study was to evaluate the rate of pediatric VTE from 2008 to 2019 using similar methodology. A retrospective cohort study using the Pediatric Health Information System (PHIS) database. Subjects from birth to <18 years admitted from 2008 through 2019 who had an ICD-9-CM or ICD-10-CM code for VTE were included. Demographics, underling medical comorbidities and mortality were collected. VTE location and anticoagulation data during admission were extracted. During the 12-year study period, there were 52 401 hospital admissions among 39 713 pediatric patients with a diagnosis of VTE. The VTE admission rate increased from 46 VTE cases per 10 000 admissions in 2008 to 106 VTE cases per 10 000 admissions in 2019, a 130% increase (P < .0001) in VTE events. The median age at admission was 6.1 years, and almost one-third (31.3%) of patients with VTE were in the adolescent age group (13–17 years). Most patients (78%) had an underlying chronic medical condition. The rate of VTE in hospitalized pediatric patients continues to increase from a 70% increase reported from 2001 to 2007 to the 130% increase from 2008 to 2019. These findings support the need for more effective VTE prevention strategies. Clinical trials focused on risk stratification and VTE prevention are needed.

29 October 2012 in Haemophilia
Verified
Journal Article
Closed access
PDF file
WWW. Wang
W. Wang
TBT. Bourgeois
T. Bourgeois
JKJ. Klima
J. Klima
EBE. D. Berlan
E. D. Berlan
AFA. N. Fischer
A. N. Fischer
SOS. H. O'BRien
S. H. O'BRien

1 December 2016 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Closed access
SJStephen Johnson
Stephen Johnson
ALAbigail Lang
Abigail Lang
MSMollie Sturm
Mollie Sturm
SOSarah H. O'BRien
Sarah H. O'BRien